Boosting Bismuth(III) Complexation for Targeted α‐Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA**-Reference-Cited by-同舟云学术

Boosting Bismuth(III) Complexation for Targeted α‐Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA**

Published:2022-09-30 Issue:43 Volume:134 Page:
ISSN:0044-8249
Container-title:Angewandte Chemie
language:en
Short-container-title:Angewandte Chemie

Author:

Horváth Dávid¹^ORCID,Vágner Adrienn²,Szikra Dezsö²³,Trencsényi György²³^ORCID,Demitri Nicola⁴^ORCID,Guidolin Nicol⁵^ORCID,Maiocchi Alessandro⁵,Ghiani Simona⁵,Travagin Fabio⁶^ORCID,Giovenzana Giovanni B.⁶^ORCID,Baranyai Zsolt⁵^ORCID

Affiliation:

1. Department of Physical Chemistry University of Debrecen Egyetem tér 1 4010 Debrecen Hungary

2. Scanomed Ltd. Nagyerdei Krt. 98 4032 Debrecen Hungary

3. Medical Imaging Clinic University of Debrecen Nagyerdei krt. 98 4032 Debrecen Hungary

4. Elettra-Sincrotrone Trieste S.S. 14 Km 163.5 in Area Science Park 34149 Basovizza (TS) Italy

5. Bracco Imaging Spa Bracco Research Centre Via Ribes 5 10010 Colleretto Giacosa (TO) Italy

6. Dipartimento di Scienze del Farmaco Università del Piemonte Orientale Largo Donegani 2/3 28100 Novara Italy

Funder

Nemzeti Kutatási Fejlesztési és Innovációs Hivatal

Università degli Studi del Piemonte Orientale

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ange.202207120

Reference40 articles.

1. Recent advances in theranostics and challenges for the future

2. Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand

3. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

4. Utilizing High-Energy γ-Photons for High-Resolution 213Bi SPECT in Mice

5. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis